Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-04-26
2008-12-30
Shiao, Rei-Tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S462000
Reexamination Certificate
active
07470724
ABSTRACT:
The invention is related to phosphonate substituted compounds having immuno-modulatory activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
REFERENCES:
patent: 5413996 (1995-05-01), Bodor
patent: 5493030 (1996-02-01), Morgans et al.
patent: 5585397 (1996-12-01), Tung et al.
patent: 5633279 (1997-05-01), Morgans et al.
patent: 5654286 (1997-08-01), Hostetler
patent: 5670497 (1997-09-01), Bold et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5750343 (1998-05-01), Maag et al.
patent: 5750493 (1998-05-01), Schinazi et al.
patent: 5811422 (1998-09-01), Lam et al.
patent: 5874577 (1999-02-01), Chen et al.
patent: 5914332 (1999-06-01), Chen et al.
patent: 6072053 (2000-06-01), Vince et al.
patent: 6174888 (2001-01-01), McQuire et al.
patent: 6312662 (2001-11-01), Robinson et al.
patent: 6319946 (2001-11-01), Hale et al.
patent: 6395763 (2002-05-01), Stamos et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 6767900 (2004-07-01), Ubasawa et al.
patent: 2001/0031773 (2001-10-01), Camden
patent: 2002/0119443 (2002-08-01), Becker et al.
patent: 2003/0109498 (2003-06-01), Yuasa et al.
patent: 2004/0121316 (2004-06-01), Birkus et al.
patent: 2004/0167096 (2004-08-01), Cheng et al.
patent: 0 267 050 (1988-05-01), None
patent: 0 441 192 (1991-01-01), None
patent: 0 465 297 (1992-01-01), None
patent: 0 531 597 (1993-03-01), None
patent: 0 632 048 (1995-01-01), None
patent: 0 786 455 (1997-07-01), None
patent: 0 852 233 (1998-07-01), None
patent: 0 919 562 (1999-06-01), None
patent: 1 295 879 (2003-03-01), None
patent: WO 88/06158 (1988-08-01), None
patent: WO91/19721 (1991-12-01), None
patent: WO 92/00988 (1992-01-01), None
patent: WO 92/18520 (1992-10-01), None
patent: WO 93/12123 (1993-06-01), None
patent: WO 93/24510 (1993-12-01), None
patent: WO 98/04569 (1995-02-01), None
patent: WO 96/14314 (1996-05-01), None
patent: WO 96/40156 (1996-12-01), None
patent: WO 97/01558 (1997-01-01), None
patent: WO 98/04569 (1998-02-01), None
patent: WO 98/11906 (1998-03-01), None
patent: WO 98/15563 (1998-04-01), None
patent: WO 99/62921 (1998-12-01), None
patent: WO 99/33815 (1999-07-01), None
patent: WO 00/04033 (2000-01-01), None
patent: WO 00/52015 (2000-08-01), None
patent: WO 00/52015 (2001-02-01), None
patent: WO 01/13957 (2001-03-01), None
patent: WO 01/17982 (2001-03-01), None
patent: WO 01/19320 (2001-03-01), None
patent: WO 01/39724 (2001-06-01), None
patent: WO 01/46204 (2001-06-01), None
patent: WO 01/64693 (2001-09-01), None
patent: WO 01/39724 (2001-10-01), None
patent: WO 01/96329 (2001-12-01), None
patent: WO 01/96354 (2001-12-01), None
patent: WO 02/03997 (2002-01-01), None
patent: WO 02/06292 (2002-01-01), None
patent: WO 02/08241 (2002-01-01), None
patent: WO 02/14344 (2002-02-01), None
patent: WO 02/48165 (2002-06-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 02/103008 (2002-12-01), None
patent: WO 03/028737 (2003-04-01), None
patent: WO 02/048165 (2003-05-01), None
patent: WO 03/050129 (2003-06-01), None
patent: WO 03/059255 (2003-07-01), None
patent: WO 03/064383 (2003-08-01), None
patent: WO 03/066005 (2003-08-01), None
patent: WO 03/080078 (2003-10-01), None
patent: WO 02/103008 (2003-11-01), None
patent: WO 03/090690 (2003-11-01), None
patent: WO 2004/096234 (2004-11-01), None
patent: WO 2004/096818 (2004-11-01), None
patent: WO 2004/096818 (2004-11-01), None
patent: WO 2005/011709 (2005-02-01), None
patent: WO 2005/011709 (2005-02-01), None
Morgans et al., 1995, CAS:124:86709.
Allen, Lee F. et al., CI-1040 (PFI84352), a Targeted Signal Transduction Inhibitor of MEK (MAPKK),Seminars in Oncology, Oct. 2003, pp. 105-116, vol. 30, No. 5, Elsevier Inc.
Bantia, Shanta et al., Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent,International Immunopharmacology, 2001, pp. 1199-1210, Elsevier Science B.V.
Beauchamp, Lilia M., et al., Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-d]pyrimidine (8-Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine Nucleoside Phosphorylase,Journal of Medicinal Chemistry, 1996, pp. 949-956, American Chemical Society.
Bohani D. W. et al., A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection,Bioorganic&Medicinal Chemistry Letters, 2004, vol. 14.
Bzowska, Agieszka et al., Purine nucleoside phosphorylases: properties, functions, and clinical aspects,Pharmacology&Therapeutics, 2000, pp. 349-425, vol. 88, Elsevier Science Inc.
Chapman, H. et al., Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340, Nucleosides, Nucleotides & Nucleic Acids, 2001, pp. 621-628, vol. 20, Nos. 4-7, Marcel Dekker, Inc.
Clark, Jeremy L. et al., Mycophenolic Acid Analogues as Potential Agents Against West Nile Virus Infection.
Conklyn, Maryrose et al., The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+cell numbers in cynomolgus monkey blood following chronic oral dosing,Journal of Leukocyte Biology, Dec. 2004, pp. 1-8, vol. 76, The Society for Leukocyte Biology.
De Clereq, E., Highlights in the Development of New Antiviral Agents,Mini Reviews in Medicinal Chemistry, 2002, 163-175, vol. 2, No. 2, Bentham Science Publishers, Ltd.
Evans, Gary B., Exploring Structure—Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase,J. Med. Chem., 2003, 3412-3423, vol. 46, No. 15, American Chemical Society.
Gumina, Giuseppe et al., Advances in antiviral agents for hepatitis B virus,Antiviral Chemistry&Chemotherapy, 2001, 93-112, vol. 12, Suppl. 1, International Medical Press.
Gobec, S. et al., Phosphonate inhibitors of antiget 85C, a crucial enzyme involved in the biosynthesis of the mycobacterium tuberculosis cell wall,Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14.
Hegedus, Louis S. et al., Synthesis of 4′-Methyl and 4′-cyano Carbocyclic 2′,3′-Didehydro Nucleoside Analogues via 1,4-Addition to Substituted Cyclopentenones,J. Org., Chem., 2004, 8492-8495, vol. 69, No. 24, American Chemical Society.
Herczegh P., et al., Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials,J. Med. Chem., 2002, vol. 45.
Hirabayashi, Hideki et al., Bone-Specific Drug Delivery Systems,Clinical Pharacokinetics, 2003, 1319-1330, vol. 42, No. 15.
Holy A. et al., Synthesis,Cllect. Czech. Chem. Commun., 1989, vol. 54, pp. 2190-2210.
Jain, Jugnu et al., Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5′-Monophosphate Dehydrogenase Inhibitor,Journal of Pharmacology and Experimental Therapeutics, 2002, 1272-1277, vol. 302, No. 3, The American Society for Pharmacology and Experimental Therapeutics.
Karpenko, Inna L. et al., Synthesis and Antitherpetic Activity of Acyclovir Phosphonates,Nucleosides, Nucleotides&Nucleic Acids, 2003, 319-328, vol. 22, No. 3, Marcel Dekker, Inc.
Kato, Keisuke et al., Stereoselective synthesis of 4′-.alpha.-alkyclcarbovir derivatives based on an asymmetric synthesis or chemo-enzymatic procedure,Chemical&Pharmaceutical Bulletin, 1999, 1256-1264, vol. 49, No. 9, Pharmaceutical Society of Japan.
Kato, Keisuke et al., Enantio-and diastereoselective syntheis of 4′-α-substituted carbocyclic nucleosides, Tetrahedron:Asymmetry, 1998, 911-914, vol. 9, Elsevier Science Ltd.
Kilpatrick, J. Michael, Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor, In vivo effects on blood 2′-deoxyguanosine in primates,International Immunopharmacology, 2003, 541-548, vol. 3, Elsevier Science B.V.
Kim, Choung Un et al., Regiospecific and Highly Stereoselective Electrophilic Addition to Furanoid Glycals: Synthesis of Phosphonate Nucleotide Analogues with Potent Activity against HIV, J. Org. Chem., 1991. 2642-2647, vol. 56, No. 8
Cannizzaro Carina
Chen James M.
Chen Xiaowu
Cho Aesop
Chong Lee S.
Gilead Sciences, Inc.
Shiao Rei-Tsang
Viksnins Harris & Padys PLLP
LandOfFree
Phosphonate compounds having immuno-modulatory activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphonate compounds having immuno-modulatory activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphonate compounds having immuno-modulatory activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4051216